Adcytherix key facts
as of Oct 2026- Developer of an antibody-drug conjugate platform designed to address resistance and improve safety in cancer therapy through novel payload innovation.
- Adcytherix is valued at approximately $213.3M as of Oct 2026, set at its early-stage round, Jul 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $160.8M across 2 recorded rounds; the latest was Early Stage VC (Series A) ($126.3M) in Jul 2025.
- Notable investors include Bpifrance, RA Capital Management, Kinled Holding, European Investment Bank, Kurma Partners — 13 tracked in total.
- Status: Privately Held (backing).
Valued at $213.3M at its early-stage round, Jul 2025. Nothing has traded since.
- ·The complete investor list: 13 names
- ·Watch Adcytherix: the Monday email on marks, rounds and moves
Adcytherix funding rounds
2 roundsWho backs Adcytherix
13+Adcytherix valuation
Adcytherix was valued at $213 million at its early-stage round in Jul 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Adcytherix raised?
Adcytherix has raised $161 million across 2 recorded rounds since 2024. The largest was a $38 million seed round in Jun 2024; the most recent was a $126 million Series A in Jul 2025.
Adcytherix investors
13 investors are on record for Adcytherix, including Bpifrance, RA Capital Management, Kinled Holding and European Investment Bank. The Series A in Jul 2025 drew 9 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Adcendo ($210 million), Plexium ($200 million) and Ajax Therapeutics ($193 million).
About Adcytherix
Developer of an antibody-drug conjugate platform designed to address resistance and improve safety in cancer therapy through novel payload innovation. The company offers new classes of payload mechanisms, advanced ADC design, and optimization beyond standard tubulin/topoisomerase inhibitors, enabling oncologists and cancer patients to benefit from effective targeted treatments with low side effects.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Marseille, France
- Founded
- 2024
- Employees
- 11
- Website
- adcytherix.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.